HC Wainwright Increases Ocugen (NASDAQ:OCGN) Price Target to $10.00

Key Points

• HC Wainwright raised its Ocugen price target from $7 to $10.00 and maintained a "buy" rating, implying roughly a 421% upside; the street average target is about $9.75 with a "Moderate Buy" consensus.
• Ocugen's Phase 2 OCU410 topline showed a 31% reduction in geographic atrophy lesion growth at 12 months with no related serious adverse events and a planned Phase 3 registrational start in Q3 2026, but the small trial size, surgical delivery complexity and regulatory risk left investors cautious and shares fell after the update.
• The stock opened around $1.92 (down ~8.6%), carries negative EPS/ROE and a ~ $630M market cap, yet several institutions (UBS, State Street, Goldman, Renaissance) materially increased positions and institutions now own about 10% of the company.

Ocugen (NASDAQ:OCGN - Get Free Report) had its price target raised by equities research analysts at HC Wainwright from $7.00 to $10.00 in a research report issued on Wednesday,Benzinga reports. The firm currently has a "buy" rating on the stock. HC Wainwright's target price indicates a potential upside of 420.83% from the stock's previous close.

OCGN has been the subject of a number of other research reports. Wall Street Zen upgraded shares of Ocugen from a "sell" rating to a "hold" rating in a research note on Saturday. Chardan Capital restated a "buy" rating and issued a $7.00 price objective on shares of Ocugen in a research note on Thursday, March 5th. Canaccord Genuity Group started coverage on shares of Ocugen in a research note on Tuesday, March 17th. They set a "buy" rating and a $12.00 target price for the company. Weiss Ratings reissued a "sell (e+)" rating on shares of Ocugen in a report on Thursday, January 22nd. Finally, Oppenheimer began coverage on Ocugen in a research report on Wednesday, March 11th. They issued an "outperform" rating and a $10.00 price target on the stock. Four research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $9.75.

Ocugen Trading Down 8.6%

OCGN opened at $1.92 on Wednesday. The company has a quick ratio of 1.06, a current ratio of 1.06 and a debt-to-equity ratio of 8.04. Ocugen has a 52 week low of $0.57 and a 52 week high of $2.72. The business's 50 day moving average is $1.73 and its two-hundred day moving average is $1.53. The firm has a market cap of $629.57 million, a price-to-earnings ratio of -8.35 and a beta of 2.75.

Ocugen (NASDAQ:OCGN - Get Free Report) last posted its quarterly earnings data on Wednesday, March 4th. The company reported ($0.06) earnings per share for the quarter, meeting the consensus estimate of ($0.06). The business had revenue of ($0.19) million during the quarter, compared to the consensus estimate of $0.86 million. Ocugen had a negative return on equity of 2,626.38% and a negative net margin of 1,192.18%. On average, research analysts predict that Ocugen will post -0.2 EPS for the current year.

Hedge Funds Weigh In On Ocugen

Several institutional investors and hedge funds have recently added to or reduced their stakes in OCGN. UBS Group AG lifted its holdings in shares of Ocugen by 373.2% in the 4th quarter. UBS Group AG now owns 4,849,353 shares of the company's stock valued at $6,547,000 after buying an additional 3,824,474 shares during the period. State Street Corp lifted its holdings in Ocugen by 193.6% in the fourth quarter. State Street Corp now owns 3,978,738 shares of the company's stock valued at $5,371,000 after acquiring an additional 2,623,361 shares during the period. Marshall Wace LLP purchased a new stake in shares of Ocugen during the 4th quarter worth $3,417,000. Goldman Sachs Group Inc. grew its stake in shares of Ocugen by 2,256.4% during the 4th quarter. Goldman Sachs Group Inc. now owns 2,302,475 shares of the company's stock worth $3,108,000 after purchasing an additional 2,204,765 shares during the period. Finally, Renaissance Technologies LLC lifted its stake in shares of Ocugen by 485.9% in the fourth quarter. Renaissance Technologies LLC now owns 1,700,400 shares of the company's stock valued at $2,296,000 after purchasing an additional 1,410,200 shares during the period. Institutional investors and hedge funds own 10.27% of the company's stock.

Ocugen News Summary

Here are the key news stories impacting Ocugen this week:

• Positive Sentiment: Phase 2 topline: OCU410 (AAV5‑RORA) showed a 31% reduction in GA lesion growth at 12 months for the medium (optimal) dose vs control (p < 0.05); no OCU410‑related serious adverse events reported and plans to start a Phase 3 registrational trial in Q3 2026. Ocugen Announces Topline 12-month Data
• Positive Sentiment: Broader validation signals: Ocugen was recently added to the S&P Biotechnology Select Industry Index and several analysts/price targets (median cited ~$10) highlight upside if later trials confirm efficacy. Ocugen Index Addition Highlights Rising Attention
• Positive Sentiment: Balance sheet context: recent coverage notes Ocugen’s cash position and runway can support near‑term development (helps fund Phase 3 planning). Ocugen Has A Healthy Cash Position For 2026
• Neutral Sentiment: Investor communications: management held a webcast/transcript to discuss the full Phase 2 dataset with KOLs and leadership, increasing transparency but also inviting scrutiny of subgroup analyses and endpoints. Ocugen to Host Webcast
• Neutral Sentiment: Short‑interest data in feeds appeared inconsistent (reports showing zeros/NaN) — market data noise rather than a clear short squeeze/cover signal. (Data anomaly reported across services.)
• Negative Sentiment: Immediate market reaction: multiple outlets reported shares fell after the trial update, suggesting the market expected either larger effect size, clearer commercial path, or was taking profits after a recent run. Ocugen falls after 12-month data
• Negative Sentiment: Key risks that can pressure the stock despite positive topline: small Phase 2 (51 patients) — limited statistical power/subgroup uncertainty; surgical subretinal delivery complexity; regulatory/confirmatory risk and company forward‑looking caveats. Market watchers may be waiting for the larger, well‑powered Phase 3 readout before assigning higher valuation. OCGN stock tanks after gene therapy trial update

About Ocugen

Ocugen Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing gene therapies to treat rare inherited retinal diseases, as well as vaccines designed to address unmet needs in infectious diseases. Headquartered in Malvern, Pennsylvania, the company applies its proprietary gene therapy platform to create novel treatments aimed at preserving and restoring vision, while leveraging strategic partnerships to broaden its vaccine pipeline.

In its gene therapy portfolio, Ocugen is advancing multiple programs targeting retinal disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.